Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus METAHYDRIN.
DIULO vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic